Menstrual hormones may worsen ADHD symptoms in medicated women

Women managing attention-deficit hyperactivity disorder with stimulant medications might experience worse symptoms during certain phases of their menstrual cycle. A recent study published in the Journal of Attention Disorders tracked daily symptom severity in adult females taking amphetamines. Tracking data revealed that ADHD symptoms and negative mood peak during the menstruation phase, pointing toward a need for personalized treatment plans that account for hormonal fluctuations.

Attention-deficit hyperactivity disorder affects approximately six percent of the adult population. The condition is characterized by chronic difficulties with focus, elevated impulsivity, and physical hyperactivity. Patients often struggle to manage their time, organize daily tasks, or regulate their emotional responses in demanding environments.

Males historically received the diagnosis at much higher rates than females, often at a ratio of three boys for every one girl. That diagnostic gap is steadily narrowing as clinicians better recognize how the condition presents in adult women. Females often express higher levels of inattentiveness and internalizing behaviors rather than outward physical hyperactivity.

This difference in symptom presentation often causes teachers and parents to miss the warning signs in young girls. Many women go undiagnosed throughout their childhood, only discovering the source of their lifelong struggles during adulthood after experiencing career or family burnout.

Despite this growing diagnostic parity, female patients remain substantially underrepresented in the scientific literature. Researchers are just beginning to investigate how female-specific biological factors interact with the disorder. One universal aspect of female biology is the natural fluctuation of ovarian hormones like estrogen and progesterone over the course of the menstrual cycle.

Case reports and anecdotal accounts have occasionally hinted that these hormonal shifts might influence both the severity of a patient’s symptoms and the effectiveness of their medication. Some women report that their medication feels entirely useless during the days immediately preceding their period, leading to days of severe impairment in their professional and social lives.

During the follicular phase, which starts after menstruation finishes, estrogen levels gradually rise and peak during ovulation. In the subsequent luteal phase occurring just after ovulation, both estrogen and progesterone are highly elevated. Both hormones then drop rapidly just prior to the onset of bleeding. Some preceding research on healthy females without neurodevelopmental conditions suggests that stimulant drugs may be less effective during this late luteal phase.

Rebecca Zaritsky, a medical and doctoral student at Rutgers University, led a research team to investigate whether these hormonal shifts affect female patients actively treated for the disorder. Her academic focus centers on how biological factors influence neurodevelopment. Zaritsky collaborated with Stephanie C. Reed and Suzette M. Evans, both researchers at Columbia University and the New York State Psychiatric Institute. Their combined expertise centers on women’s health issues related to substance use and the menstrual cycle.

The team designed their study to fill a specific knowledge gap regarding females prescribed amphetamine salts. This category of medication operates by altering brain chemistry to improve focus and includes widely recognized brand names such as Adderall and Mydais. Over sixty percent of reproductive-age females medicated for the disorder in the United States rely on amphetamine salts. The researchers wanted to see if the therapeutic benefits of these daily medications fluctuated in tandem with the menstrual cycle.

The researchers recruited adult females with regular menstrual cycles between the ages of eighteen and forty. All thirty final participants had a formal diagnosis of the disorder and took amphetamine salts for symptom management on most days of the week. Most participants reported receiving their initial diagnosis during their mid-twenties, reflecting the common delays in identifying the condition in females. The participants also indicated that they took their medication nearly every single day, reinforcing how heavily they relied on the treatment.

To isolate the potential effects of natural hormonal cycles, the study excluded individuals taking hormonal birth control pills or other psychiatric medications. The participants agreed to complete daily online surveys for thirty-five consecutive days. This extended timeline was deliberately chosen to consistently capture data across one complete menstrual cycle for all participants.

Each evening, the participants answered standardized questions evaluating their current mood and the severity of their symptoms. They rated the frequency of eighteen different inattentive and hyperactive behaviors on a four-point sliding scale ranging from rarely to very often. They also reported their total daily medication dosage in milligrams and noted whether they were actively menstruating or spotting.

Analyzing the daily survey responses revealed clear patterns in symptom severity across the month. Participants reported higher levels of symptom severity during the menstruation phase. Conversely, they experienced milder symptoms during the mid-follicular phase. The difference in symptom expression between the late luteal phase and the mid-follicular phase was not statistically significant.

The team also evaluated general psychological well-being alongside the primary symptoms of the disorder. Participants reported elevated negative mood during both the menstruation phase and the late luteal phase compared to the mid-follicular phase. Changes in negative mood closely tracked with the severity of the primary condition.

Participants who reported greater increases in negative mood during their period also logged greater increases in their attention and hyperactivity symptoms. The magnitude of this mood change served as a reliable predictor for subjective experiences of inattention. Patients who struggled the most with sadness or irritability were the same individuals who struggled worst with focus.

The exact reasons for this alignment between mood and symptom severity remain unconfirmed. Worsening attention could naturally lead to feelings of low mood and emotional frustration. Alternatively, feelings of depression and physical fatigue could make it harder for patients to manage the executive function required for focus. It is also possible that dropping estrogen levels trigger a unified biological cascade that simultaneously drives both depression and distraction.

The researchers initially hypothesized that patients might try to counteract these difficult menstrual phases by taking higher doses of their prescribed stimulants. The survey data did not support this idea. Daily amphetamine dosage remained entirely consistent across all phases of the cycle.

This lack of dosage adjustment might reflect standard medical practices. Most prescribing physicians do not encourage flexible, symptom-based dosing regimens for these types of heavily regulated medications. Patients might also be entirely unaware that their medication metabolism and efficacy could wane alongside their physical hormonal shifts.

The authors noted several limitations to their interpretation of the data. The study relied entirely on self-reported surveys from a relatively small group of thirty individuals. This reliance on remote self-reporting means the objective accuracy of the data cannot be independently verified.

The self-reported questionnaires also limit the ability to tell if symptoms objectively worsened or if they were only perceived to be worse by the distressed participants. The study protocol also did not involve direct blood tests to verify exact hormone levels in the participants.

Without tracking precise estrogen and progesterone markers, the researchers could only approximate the internal hormonal environment based on the normal timing of human menstruation. The researchers were unable to study other unique phases of interest, such as the exact moments of highest fertility right after ovulation.

Additionally, excluding participants who navigate simultaneous mood disorders or who take hormonal birth control limits how broadly these results apply to the general public. Future research featuring larger participant pools and direct medical observation could help clarify how hormones interact with brain chemistry and prescription drugs. Expanding the scope to include women navigating puberty, pregnancy, or menopause could also yield a more thorough understanding of the female experience.

Pending varied and expanded data, the new findings point toward alternative types of clinical interventions that might eventually improve daily life for female patients. Educational initiatives could empower women to schedule demanding tasks around the days they feel most capable. Clinicians might also explore alternative prescribing strategies, temporarily increasing stimulant dosages during specific menstrual phases to combat dropping medication efficacy.

If these symptom fluctuations continue to cause distress, clinicians might eventually consider a wider range of pharmacological interventions. Some patients might benefit from utilizing oral contraceptives to reduce the natural hormonal fluctuations that trigger symptom spikes. Other individuals might find relief through the targeted use of antidepressant medications to ameliorate negative mood disruptions during specific cycle phases. Each of these potential interventions requires substantial future investigation to confirm their effectiveness and safety.

The study, “Changes in ADHD Symptoms and Mood Across the Menstrual Cycle in Females Treated With Stimulants: A Pilot Study,” was authored by Rebecca Zaritsky, Stephanie C. Reed, and Suzette M. Evans.